



Article

Regulation of Pleiotrophin and PTPRZ1 Expression by Hypoxia to Restrict Hypoxia-Induced Cell Migration

Evangelia Poimenidi ^{1,2,†}, Eirini Droggiti ¹, Katerina Karavasili ¹, Dimitra Kotsirilou ^{1,2}, Eleni Mourkogianni ¹, Pieter Koolwijk ² and Evangelia Papadimitriou ^{1,*}

- Laboratory of Molecular Pharmacology, Department of Pharmacy, University of Patras, 26504 Patras, Greece; evipoi@yahoo.com (E.P.)
- ² Department of Physiology, Amsterdam UMC, 1081 HV Amsterdam, The Netherlands
- * Correspondence: epapad@upatras.gr; Tel.: +30-2610962336
- [†] Current address: Anaesthesia and Intensive Care Medicine, Leicester Royal Infirmary, University Hospitals of Leicester, Leicester LE1 5WW, UK.

Simple Summary: Hypoxia regulates gene expression to support tumor cell invasion and angiogenesis. Hypoxia-inducible transcription factors (HIFs) play a major role in the hypoxia effects through interactions with other transcription factors, such as AP-1. Pleiotrophin (PTN) acts through protein tyrosine phosphatase receptor zeta 1 (PTPRZ1) and regulates cell migration in a manner that depends on $\alpha_{\rm V}\beta_3$ integrin expression. The present study shows that hypoxia or chemical hypoxia increases the PTN expression in endothelial and glioblastoma cells that express $\alpha_{\rm V}\beta_3$ integrin in a HIF- and AP-1-dependent manner to negatively impact the stimulatory effect of hypoxia on endothelial cell proliferation and migration. The expression of PTPRZ1 is also enhanced by hypoxia, is HIF-dependent, and limits the activation of HIF-1 α in endothelial cells. In conclusion, hypoxia or chemical hypoxia regulates PTN and PTPRZ1 expression to restrict its stimulatory effects on endothelial and cancer cells.



Academic Editor: Anders M. Ström

Received: 21 March 2025 Revised: 17 April 2025 Accepted: 24 April 2025 Published: 30 April 2025

Citation: Poimenidi, E.; Droggiti, E.; Karavasili, K.; Kotsirilou, D.; Mourkogianni, E.; Koolwijk, P.; Papadimitriou, E. Regulation of Pleiotrophin and PTPRZ1 Expression by Hypoxia to Restrict Hypoxia-Induced Cell Migration. *Cancers* 2025, 17, 1516. https://doi.org/10.3390/ cancers17091516

Copyright: © 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

Abstract: Background/Objectives: In the tumor microenvironment, hypoxia regulates genes that support tumor cell invasion and angiogenesis under the control of the hypoxiainducible transcription factors (HIFs). Pleiotrophin (PTN) is a secreted protein that activates cell migration in endothelial and cancer cells that express $\alpha_V \beta_3$ integrin but has inhibitory effects in cells that do not express $\alpha_{\gamma}\beta_{3}$ integrin. In both cases, the protein tyrosine phosphatase receptor zeta 1 (PTPRZ1) seems to mediate the effects of PTN. In the present work, we studied the effect of hypoxia on PTN and PTPRZ1 expression and the functional consequences of this effect. Methods: Western blot, quantitative real-time PCR, and luciferase assays were used to study the impact of hypoxia at the protein, mRNA, and transcriptional levels, respectively. Decoy oligonucleotides (ODNs), siRNA technology, and plasmid overexpression were used to study the involvement of the transcription factors studied. Functional assays were used to study the effect of hypoxia on cell proliferation and migration. Results: Hypoxia increases PTN expression through the transcriptional activation of the corresponding gene in $\alpha_{\nu}\beta_3$ integrin-expressing cells. The transcription factors HIF- 1α , HIF- 2α , and AP-1 mediate the up-regulation of PTN by hypoxia. Functional assays in endothelial cells from PTN knockout mice or endothelial and cancer cells following the downregulation of PTN expression showed that PTN negatively affects chemical hypoxia-induced cell proliferation and migration. In cancer cells that do not express $\alpha_{\gamma}\beta_3$ integrin, hypoxia or chemical hypoxia inhibits PTN expression in a HIF-1 α -, HIF-2 α -, and AP-1-independent manner. The expression of PTPRZ1 is up-regulated by chemical hypoxia, is HIF-1 α - and HIF-2 α -dependent, and seems to limit the activation of HIF-1 α , at least in endothelial cells. Conclusions: Hypoxia or chemical hypoxia regulates PTN and

Cancers 2025, 17, 1516 2 of 17

PTPRZ1 expressions to restrict the stimulatory effects of hypoxia on endothelial and cancer cell migration.

Keywords: angiogenesis; cancer; endothelial cells; hypoxia; integrin; tyrosine phosphatase

1. Introduction

Hypoxia is present in several physiological and pathological conditions due to a decreased supply or increased demand for O₂, and all organisms have developed mechanisms to adapt to hypoxia. The key mediators of this adaptive response are the hypoxia-inducible factors (HIFs) that trigger the transcription of multiple genes and regulate processes, such as glucose metabolism, cell survival, proliferation, apoptosis, and angiogenesis. To date, three isoforms of HIFs have been found: HIF-1, HIF-2, and HIF-3. HIFs are heterodimers comprising a constitutively expressed beta (β) subunit and a regulated alpha (α) subunit. In the presence of oxygen, the α subunit is hydroxylated on two prolines by specific oxygen prolyl hydroxylases, and the hydroxylated form interacts with the von Hippel-Lindau protein, which targets this subunit for degradation by the proteasome. Under hypoxic conditions, the α subunit is not hydroxylated, which results in its stabilization and translocation into the nucleus, where it dimerizes with the β subunit, forming the active HIF transcription factor that binds to the hypoxia response element (HRE) present in the promoter of its target genes [1,2]. Another redox-sensitive, hypoxia-activated transcription factor is AP-1, which plays roles in cell proliferation, apoptosis, inflammation, migration, differentiation, and angiogenesis by affecting the expression of numerous genes [3-6], including pleiotrophin [7].

Pleiotrophin (PTN) is a secreted growth factor that induces migration in cells expressing $\alpha_{\nu}\beta_{3}$ integrin, including endothelial cells [8,9]. However, PTN has also been shown to inhibit cell migration in cells that lack $\alpha_{\nu}\beta_{3}$ integrin expression [9,10]. Among the numerous receptors that regulate the effects of PTN on endothelial cells [11], the protein tyrosine phosphatase receptor zeta 1 (PTPRZ1) is of great importance [8,12]. PTPRZ1 plays a key role in regulating cell migration [13] and acts as a receptor for cytokines and growth factors, e.g., VEGFA₁₆₅ [12,14]. PTN is upregulated by hypoxia in rat hepatic stellate cells [15], in a rat model of myocardial infarction [16], or after acute ischaemic brain injury [17]. It remains unclear, however, how hypoxia affects PTN expression and whether PTN has a role in the effects of hypoxia in different types of cells. On the other hand, PTPRZ1 is up-regulated by both the HIF-2 α [18,19] and HIF-1 α [20] that act through the HREs found in the *Ptprz1* gene promoter. The functional significance of the PTPRZ1 up-regulation by hypoxia is still unknown.

In the present work, we investigated the effect of hypoxia on the expression of PTN and PTPRZ1, identified the role of the HIFs and AP-1 transcription factors, and clarified their functional significance on hypoxia-induced cell migration.

2. Materials and Methods

2.1. Cells

The endothelial cells used in the present study were human umbilical vein endothelial cells (HUVECs), and lung microvascular endothelial cells (LMVECs) derived from wild-type C57BL/6J mice ($Ptn^{+/+}$), C57BL/6J knockout mice for PTN ($Ptn^{-/-}$), wild-type SV129/B6 mice ($Ptprz1^{+/+}$), and SV129/B6 knockout mice for PTPRZ1 ($Ptprz1^{-/-}$). In all cases, endothelial cells were isolated as previously described [12,21]. We also used human glioblastoma U87MG and M059K cells, rat C6 glioma cells [9], and human prostate cancer

Cancers 2025, 17, 1516 3 of 17

LNCaP cells that were stably transfected with the pCDNA3.1 control vector (LNCaP-PC), or with the same vector carrying an antisense ptn gene (LNCaP-AS) [22]. Cell culture media contained penicillin 100 U/mL /streptomycin 100 μ g/mL, gentamycin 50 μ g/mL, and amphotericin 2.5 μ g/mL, and cultures were maintained at 37 °C, 5% CO₂, and 100% humidity.

2.2. Hypoxia

A custom-designed hypoxic workstation (T.C.P.S, Rotselaar, Belgium) equipped with an oxygen transmitter (GE Panametrics, Billerica, MA, USA), which includes a CO₂- and O₂-controlled humidified incubator (Sanyo, Ettenleur, The Netherlands) placed inside a T4 glove box (Jakomex, Dagneux, France), was used. An internal zirconia sensor monitored the oxygen concentration. All cell culture media and buffers were pre-incubated into the hypoxic workstation for 4 h before use [23]. The Anaerocult® A system (Merck Millipore, Darmstadt, Germany, #1.01611.0001) created the hypoxic 0.2% O₂ atmosphere. Chemical hypoxia was achieved by incubating cells with either deferoxamine (DFX) at a final concentration of 200 µM (deferoxamine mesylate, Merck, Germany, #252750) or dimethyloxalylglycine (DMOG), at a final concentration of 0.5 mM (Santa Cruz Biotechnology, Heidelberg, Germany, #sc-200755). These concentrations induced optimal up-regulation of HIF- 1α (Supplementary Figure S1A). DFX chelates iron leading to the accumulation of HIF- α and its translocation from the cytoplasm to the nucleus, where it dimerizes with HIF-1 β , to become transcriptionally active [24]. DMOG is a cell-permeable, competitive inhibitor of the prolyl-hydroxylases that stabilize HIF- α [1]. When cells reached 80–90% confluence, they were serum-starved with medium containing 5% FBS for 16 h before treatment with DFX, DMOG, or low O₂. The effect of the different types of hypoxia on the levels of PTN expression was not the focus of this study since the Western blot assay has the limitation of being semi-quantitative.

2.3. Transient Cell Transfection

Plasmid pEGFP-HIF-1 α and pEGFP-HIF-2 α constructs have been previously described [25,26]. The pcDNA3.1-GFP vector was used as a control. C6 and M059K cells, at 50% confluency, were incubated with the plasmid DNA and the suitable transfection reagents, which were jetPEITM in C6 cells or jetPEI-HUVECTM in M059K cells (both from Polyplus Transfection, #101-10N and #108-01N, respectively). In both cases, a N/p = 5 ratio was used, and cells were incubated with the transfection medium for 4 h at 37 °C and then with fresh serum-containing medium 24 h later before assaying for the expression of HIFs and VEGFA (positive control), PTN, or PTPRZ1 by Western blot analysis.

2.4. RNA Interference

To down-regulate PTPRZ1 expression, C6 cells or LNCaP cells at 60% confluency were incubated in a transfection medium (Santa Cruz Biotechnology Inc., #sc-36868) containing 80 nM annealed siRNA for PTPRZ1 [14,27] and siRNA transfection reagent (Santa Cruz Biotechnology Inc., #sc-29528) for 6 h. The medium was replaced with the corresponding full medium, and cells were cultured for 48 h before being used for further experiments. To down-regulate HIF-1 α or HIF-2 α , HUVECs (30 \times 10⁴ on 10 cm²) were transfected in 2 mL culture medium containing 2.5 μ L DharmaFECT transfection reagent Type 1 (GE Dharmacon Lafayette, Lafayette, CO, USA) and 1 μ g siRNA (dssiRNA for HIF-1 α or HIF-2 α , Qiagen, Venlo, The Netherlands). HUVECs were placed in the electroporation system (Amaxa, Lonza Verviers, Belgium) according to the manufacturer's instructions, and cultured for 18 h after transfection, before starting further experiments [23]. Double-stranded negative control siRNA (Ambion Inc., Austin, TX, USA, Silencer^R Negative Control siRNA, #AM4635) was used in all cases.

Cancers 2025, 17, 1516 4 of 17

2.5. Western Blot Analysis

Proteins were analyzed by SDS-PAGE and transferred to Immobilon P membranes. Blocking was performed by incubating the membranes with Tris-buffered saline (TBS), pH 7.4, with 0.1% Tween, containing 5% nonfat dry milk. Membranes were further incubated with PTN monoclonal antibody (M01) clone 5C3 (1:1000, Abnova, Heidelberg, Germany, #H00005764-M01), mouse anti-PTPRZ1 (1:500, BD Biosciences (Franklin Lakes, NJ, USA, #610180), GFP (D5.1) rabbit mAb (1:200, Cell Signaling Technology (Danvers, MA, USA, #2956), rabbit polyclonal VEGF Antibody (A-20) (1:250, Santa Cruz Biotechnology, #sc-152), HIF-1 α (D1S7W) XP[®] Rabbit mAb (1:1000, Cell Signaling Technology, #36169), or mouse monoclonal actin antibody (2Q1055) (1:2000, Santa Cruz Biotechnology, #sc-58673) for 16 h at 4 °C under continuous agitation, washed 3 times with TBS-T, and incubated with horseradish peroxidase-conjugated anti-mouse IgG (Cell Signaling Technology; #7076) or anti-rabbit IgG (Cell Signaling Technology; #7074) for 1 h at room temperature. The membranes were washed, and the immunoreactive bands were detected using the enhanced chemiluminescence (ECL) detection kit (Pierce Biotechnology, Rockford, IL, USA), according to the manufacturer's instructions. The protein levels corresponding to the immunoreactive bands were quantified using the ImageJ image analysis software (version 1.53e). Unless otherwise stated, the PTN/PTPRZ1 signal was normalized to the β -actin (loading control) signal for the corresponding sample.

2.6. Quantitative Real-Time PCR Analysis

RNA isolation of HUVECs from at least 4 donors was performed using the RNeasy Mini Kit (Qiagen, Venlo, The Netherlands). cDNA was synthesized using the Cloned AMV First Strand c DNA Synthesis Kit from Invitrogen (Waltham, MA, USA) with poly(T)primers. Oligonucleotides were designed and used as previously described [28]. Quantitative real-time PCR using SYBR Green was performed in duplicate wells in an ABI 7500 sequence detection system (Applied Biosystems, Foster City, CA, USA). As an endogenous reference gene, we used β 2-microglobulin, and the relative expression level of PTN was calculated using the comparative Ct method, as previously described [28].

2.7. Transient Transfection and Luciferase Assay

Plasmid constructs containing the full-length promoter of the wild-type human ptn gene or the full-length promoter of the human ptn gene carrying point mutations in both AP-1-like motifs, fused to a luciferase reporter gene, were used as previously described [7]. U87MG or M059K cells were cultured in 12-well plates (4 \times 10⁵ cells/well) overnight, before being incubated in 1 mL of serum-free medium containing 1.5 μ g of plasmid DNA and 4 μ L of jetPEITM transfection reagent, for 4 h at 37 °C. The transfection medium was replaced by a fresh medium, and 16 h later, the culture medium was replaced with a medium containing DFX for different periods. Luciferase activity was determined using the luciferase reporter gene assay from Roche Applied Science (Indianapolis, IN, USA), according to the manufacturer's instructions. Cell lysates were analyzed for protein content using the Bradford method, and luminescence units were normalized for total protein content [7].

2.8. Decoy Oligonucleotide (ODN) Technique

The single-stranded phosphorothioate-bonded ODNs for AP-1 and HIFs (HIF-1 and HIF-2) used in the present study are based on previous studies [7,29] and shown in Supplementary Table S1. Complementary single-stranded ODNs were incubated at 95 °C for 5 min followed by a cool-down phase of 3 h at ambient temperature, to form the double-stranded ODNs to be used. The efficiency of the hybridization reaction was verified in 2.5% agarose gels and always exceeded 95%. HUVECs were seeded in 6-well plates at 80% confluency

Cancers 2025, 17, 1516 5 of 17

and after 24 h were incubated with the double-stranded ODNs (450 nM) and 6 μ L of jetPEITM in 1 mL of serum-free medium for 4 h before performing further experiments.

2.9. Proliferation Assay

LMVECs were plated in 48-well plates (1.5×10^4 cells/well). When cells reached 70–80% confluency, they were serum-starved overnight and then incubated with the tested agents for 24 h in the serum-starved medium. The cells were then harvested by trypsin and counted using a hemocytometer.

2.10. Migration Assays

Migration assays were performed in 24-well microchemotaxis chambers (Corning, Inc., Lowell, MA, USA) using uncoated polycarbonate membranes with 8 μm pores. Cells were serum-starved and suspended in serum-free medium containing 0.25% BSA (10 5 cells/0.1 mL). The bottom chamber was filled with 0.6 mL of serum-free medium containing 0.25% BSA and the tested agents whenever applied. The upper chamber was loaded with 0.1 mL of the cell suspension and the transwell was incubated for 4 h at 37 $^{\circ}$ C. The cells on the membranes were fixed, stained with 0.33% toluidine blue or 1% crystal violet solution, and, in the case of endothelial cells, quantified on the entire area of each membrane using a grid and a microscope (Optech Microscope Services Ltd., Oxfordshire, UK) using the 20X objective. Two independent researchers blindly counted each membrane. In the case of cancer cells, crystal violet was extracted from the membranes by 200 μ L of a 10% acetic acid solution, transferred to 96-well plates, and counted on a photometer at 630 nm.

2.11. Statistical Analysis

All data is derived from at least three independent experiments. All results are expressed as mean \pm SD, and the significance of variability between the experimental and the corresponding control groups was determined by unpaired t-test or ANOVA as required.

3. Results

3.1. Hypoxia Stimulates PTN Expression Through Increased Transcription of Corresponding Gene

To study whether hypoxia affects the PTN expression by HUVECs, we cultured the cells under hypoxic conditions and measured PTN protein amounts normalized to the corresponding β -actin protein amounts. As shown in Figure 1, PTN protein levels in HUVECs were significantly increased 24 h after the application of hypoxia, both in a hypoxic station (Figure 1A) and in Anaerocult A bags (Figure 1B), as well by the application of chemical hypoxia by incubating HUVECs with DFX or DMOG (Figure 1C). PTN mRNA levels were significantly increased 24 h after hypoxia application in HUVECs (Figure 1D), suggesting that hypoxia enhances PTN expression. To evaluate whether the effect of hypoxia on PTN is observed at the transcriptional level, we used a plasmid construct containing the full-length promoter of the human PTN gene fused to a luciferase reporter gene [7] to transfect U87MG cells. We could not use HUVECs for such assays, due to their inefficient transfection with the reporter gene. U87MG cells were chosen because they express $\alpha_{\nu}\beta_3$ integrin and PTN enhances their migration, similarly to HUVECs [9]. Before performing the luciferase assays, we verified that chemical hypoxia up-regulates PTN protein levels in U87MG cells (Supplementary Figure S1B). The reporter activity was increased in response to chemical hypoxia (Figure 1E), suggesting that hypoxia up-regulates PTN expression at the transcriptional level.

Cancers 2025, 17, 1516 6 of 17




Figure 1. Hypoxia enhances the expression of PTN in endothelial cells. (**A–C**) Representative Western blot for PTN and β-actin following a 24 h incubation of HUVECs in an oxygen atmosphere of 1% (**A**), in Anaerocult A bags (hypoxia 0.2%) (**B**), or in a treatment with DFX (200 μM) or DMOG (0.5 mM) (**C**). Results are expressed as the mean \pm SD (n = 3) of the percentage change in the PTN protein levels compared with the corresponding normoxia or untreated cells (untr, set by default as 100%). N, normoxia; H, hypoxia. (**D**) PTN mRNA levels after HUVEC incubation in an oxygen atmosphere of 1% for 24 h. Results are expressed as the mean \pm SD (n = 3) of the percent change in the PTN mRNA level compared to the normoxia-treated cells. (**E**) U87MG cells were transfected with the full-length promoter of the wild-type human *AP-1* gene fused to a luciferase reporter gene. The luciferase activity at different time points after adding DFX in the cell culture medium was normalized to the total protein content. Results are expressed as the mean \pm SD (n = 3) of the percent change in the luciferase activity compared to the untreated cells (untr) at 3 h (set by default as 100%).

3.2. HIF-1α and HIF-2α Are Involved in the Hypoxia-Induced PTN Up-Regulation

To determine whether HIFs are involved in the hypoxia-induced PTN expression, we used HIF ODNs (dHIF) that inhibit both HIF- 1α and HIF- 2α [29]. When HUVECs were transfected with ODNs containing a mutated HRE consensus sequence (mHIF), hypoxia upregulated the PTN expression, like its effect on untransfected HUVECs. At the same time, the transfection with dHIF ODNs inhibited the stimulatory effect of hypoxia

Cancers 2025, 17, 1516 7 of 17

(Figure 2A). To see whether this effect is specifically due to HIF- 1α or HIF- 2α , we down-regulated their expression by siRNA in HUVECs (Supplementary Figure S2A), as previously described [23]. The decreased HIF- 1α or HIF- 2α expression did not affect the hypoxia-induced mRNA levels of PTN (Figure 2B). On the other hand, the overexpression of HIF- 1α or HIF- 2α in U87MG cells (Supplementary Figure S2B) increased the PTN protein levels (Figure 2C). Altogether, these data support a redundant role of HIFs in the PTN up-regulation by hypoxia.




Figure 2. HIFs are involved in the hypoxia-induced PTN up-regulation in endothelial cells. (**A**) The representative Western blot for PTN following a 24 h incubation of HUVECs in 0.2% oxygen. Cells were either untreated (untr) or treated with ODNs containing the HIF- α consensus sequence (dHIF) or treated with ODNs containing the mutated HIF- α consensus sequence (mHIF). Results are expressed as the mean \pm SD (n = 4) of the percent change in the relative PTN protein levels compared with the untreated cells cultured in normoxic conditions. ns, non-significant. (**B**) PTN mRNA levels after HUVEC incubation in 1% oxygen for 24 h following the downregulation of HIF-1α (siHIF-1α) or HIF-2α (siHIF-2α). siNeg corresponds to cells treated with a negative control siRNA sequence. Results are expressed as the mean \pm SD (n \geq 3) of the percent change in PTN mRNA levels compared to the corresponding normoxia-treated cells (set by default as 100% in each case). (**C**) U87MG cells were transfected with pEGFP-HIF-1α (HIF-1α), pEGFP-HIF-2α (HIF-2α), or the pcDNA3.1-GFP vector (vector). Cell lysates were analyzed by a Western blot for PTN and β-actin, and results are expressed as the mean \pm SD (n = 3) of the percentage change in the PTN protein levels compared with the untreated cells.

Cancers 2025, 17, 1516 8 of 17

3.3. AP-1 Is Involved in the Hypoxia-Induced PTN Expression

Since hypoxia is also known to activate the AP-1 transcription factor [3–6], and the *ptn* gene promoter contains two AP-1 binding sites [7], we tested whether the hypoxia-induced PTN expression is due to hypoxia-induced AP-1 activation. The transfection of HUVECs with AP-1 ODNs before the hypoxia application resulted in marked attenuation of the hypoxia-induced PTN protein up-regulation. ODNs containing a mutated AP-1 consensus sequence had no effect (Figure 3A). We then examined the contribution of the AP-1 motifs of the human *ptn* promoter to the increased transcription of the *ptn* gene in hypoxia-treated U87MG cells. For this reason, we used the plasmid construct containing the full-length promoter of the human *ptn* gene fused to a luciferase reporter gene, as well as a construct with point mutations in both AP-1-like motifs [7] to transfect U87MG cells, as described in the Materials and Methods Section. Chemical hypoxia increased the reporter activity of the wild-type *ptn* promoter (wtAP-1) but not the reporter activity of the AP-1 double mutant (mutAP-1), suggesting that AP-1 may be involved in the hypoxia-induced transcription of the *ptn* gene (Figure 3B).




Figure 3. AP-1 is involved in the hypoxia-induced PTN expression. (**A**) The representative Western blot for PTN following a 24 h incubation of HUVECs in Anaerocult A bags (hypoxia 0.2%). Cells were either untreated (untr) or treated with ODNs containing the AP-1 consensus sequence (dAP-1) or treated with ODNs containing the mutated AP-1 consensus sequence (mAP-1). Results are expressed as the mean \pm SD (n = 4) of the percentage change in the PTN protein levels compared with the untreated cells cultured in normoxic conditions. (**B**) U87MG cells were transfected with the full-length promoter of the wild-type human *AP-1* gene (wtAP-1) or the full-length promoter of the human *ptn* gene carrying point mutations in both AP-1-like motifs (mutAP-1), fused to a luciferase reporter gene. The luciferase activity 24 h after adding DFX (200 μ M) in the cell culture medium was normalized to the total protein content. Results are expressed as the mean \pm SD (n = 3) of the percent change in the luciferase activity compared to the untreated cells transfected with the wtAP-1 construct (set by default as 100%). ns, non-significant.

Cancers 2025, 17, 1516 9 of 17

3.4. PTN Expression Inhibits Hypoxia-Induced Endothelial Cell Proliferation and Migration

To investigate whether hypoxia-induced PTN expression has a functional significance in hypoxia-induced endothelial cell proliferation and migration, we used LMVECs isolated from C57BL/6 mice that are a knockout for PTN and studied the effect of chemical hypoxia on their proliferation and migration compared to the wild-type LMVEC. In $Ptn^{+/+}$ LMVECs, hypoxia up-regulates the PTN protein levels (Supplementary Figure S3A), similarly to HUVECs. Figures 4A and S3B show that DFX and DMOG induce $Ptn^{-/-}$ and $Ptn^{+/+}$ LMVEC proliferation, and the effect of chemical hypoxia is significantly higher in $Ptn^{-/-}$ compared to $Ptn^{+/+}$ LMVECs. Like proliferation, both DFX and DMOG have a substantially greater impact on the migration of $Ptn^{-/-}$ compared with $Ptn^{+/+}$ LMVECs (Figures 4B and S3C). Besides endothelial cells, in human prostate cancer LNCaP cells that are stably transfected with an antisense sequence and express significantly reduced levels of PTN [22] hypoxia resulted in a significantly higher induction of migration compared with the corresponding cells transfected with the plasmid control vector (Supplementary Figure S4).




Figure 4. PTN expression inhibits hypoxia-induced endothelial cell proliferation and migration. (**A**) $Ptn^{+/+}$ and $Ptn^{-/-}$ LMVECs were incubated for 24 h with 0.5 mM of DMOG or 200 μM of DFX and cell numbers were determined by direct counting. Results are expressed as the mean \pm standard deviation (n = 3) of the percent (%) number of cells compared to the corresponding untreated cells (set by default as 100%). (**B**) $Ptn^{+/+}$ and $Ptn^{-/-}$ LMVECs were incubated for 4 h with 0.5 mM of DMOG or 200 μM of DFX, and migration was studied using the transwell assay. Results are expressed as the mean \pm standard deviation (n \geq 3) of the % number of cells compared to the corresponding untreated cells (untr, set by default as 100%).

3.5. Hypoxia Decreases PTN Expression in Glioblastoma Cells That Do Not Express $\alpha_{\gamma}\beta_3$ Integrin

We have previously shown that PTN activates cell migration in endothelial and U87MG glioblastoma cells that express $\alpha_{\nu}\beta_{3}$ integrin but inhibits cell migration in C6 and M059K cells that do not express $\alpha_{\nu}\beta_{3}$ integrin [9,27]. To study whether hypoxia affects the PTN expression in cells that do not express $\alpha_{\nu}\beta_{3}$ integrin (Supplementary Figure S5), we incubated C6 and M059K cells with DFX and/or DMOG for 24 h and looked for their effect on PTN expression. Opposite to their stimulatory effect on endothelial cells, DFX and DMOG decreased the PTN protein levels in C6 (Figure 5A) and M059K (Figure 5B) cells. In the latter cells, a hypoxia of 0.2% for 24 h also decreased the PTN protein levels (Figure 5C). The overexpression of HIF-1 α and HIF-2 α increased VEGFA protein levels as expected (Supplementary Figure S6) but did not affect the PTN protein levels in C6 cells (Figure 5C). AP-1 is not involved in the inhibitory effect of hypoxia, since when we examined the contribution of the AP-1 motifs of the human *ptn* promoter to the increased transcription of the *ptn* gene in DFX-treated M059K cells, we found that chemical hypoxia

Cancers 2025, 17, 1516 10 of 17

decreased the reporter activity of both the wild-type (wtAP-1) and the AP-1 double mutant *ptn* (mutAP-1) promoter (Figure 5D).




Figure 5. Effect of hypoxia on PTN expression in glioblastoma cells that lack $\alpha_{\nu}\beta_{3}$ integrin expression. C6 (A) and M059K (B) cells were treated with DMOG (0.5 mM) or DFX (200 μ M) for 24 h. Cell lysates were analyzed by Western blot for PTN and β -actin, and results are expressed as mean \pm SD (n = 4) of percentage change in relative PTN protein levels compared with untreated cells. (C) Representative

Cancers 2025, 17, 1516 11 of 17

Western blot for PTN and β -actin following 24 h incubation of M059K cells in Anaerocult A bags (hypoxia 0.2%). Results are expressed as mean \pm SD (n = 3) of percentage change in PTN protein levels compared with normoxia-treated cells (set by default as 100%). N, normoxia; H, hypoxia. (**D**) C6 cells were transfected with pEGFP-HIF-1 α (HIF-1 α), pEGFP-HIF-2 α (HIF-2 α), or pcDNA3.1-GFP vector (vector). Cell lysates were analyzed by Western blot for PTN and β -actin, and results are expressed as mean \pm SD (n = 6) of percentage change in PTN protein levels compared with untreated cells. (**E**) M059K cells were transfected with full-length promoter of wild-type human *AP-1* gene (wtAP-1) or full-length promoter of human *AP-1* gene carrying point mutations in both AP-1-like motifs (mutAP-1), fused to luciferase reporter gene. Luciferase activity 24 h after adding DFX in cell culture medium was normalized to total protein content. Results are expressed as mean \pm SD (n = 3) of percent change in luciferase activity compared to untreated cells transfected with wtAP-1 construct (set by default as 100%).

3.6. The Interplay Between Hypoxia and PTPRZ1

Since PTN largely acts through PTPRZ1, which both HIF-1 α [20] and HIF-2 α [18,19] up-regulate, we studied the effect of chemical hypoxia on the proliferation and migration of LMVECs derived from $Ptprz1^{+/+}$ and $Ptprz1^{-/-}$ mice. DFX and DMOG significantly enhanced the proliferation (A) and migration (B) of both $Ptprz1^{+/+}$ and $Ptprz1^{-/-}$ LMVECs. The effect of DFX and DMOG on LMVEC proliferation was similar, independent of the expression of PTPRZ1. However, their impact on $Ptprz1^{-/-}$ LMVEC migration was significantly smaller than that on $Ptprz1^{+/+}$ LMVECs (Figures 6 and S7). Likewise, in human prostate cancer LNCaP and rat glioma C6 cells, the downregulation of the PTPRZ1 expression by siRNA resulted in a smaller increase in the cell migration induced by hypoxia or DMOG, respectively (Supplementary Figure S8A,B). In both LNCaP and C6 cells, the downregulation of PTPRZ1 significantly enhanced cell migration (Supplementary Figure S8C,D), like what we have observed in $Ptprz1^{-/-}$ LMVECs (Supplementary Figure S7 and [12]).




Figure 6. The effect of PTPRZ1 expression on the hypoxia-induced endothelial cell proliferation and migration. (**A**) $Ptprz1^{+/+}$ and $Ptprz1^{-/-}$ LMVECs were incubated for 24 h with 200 μ M of DFX or 0.5 mM of DMOG and cell numbers were determined by direct counting. Results are expressed as the mean \pm standard deviation (n = 3) of the % number of cells compared to the corresponding untreated cells (set by default as 100%). ns, non-significant. (**B**) $Ptprz1^{+/+}$ and $Ptprz1^{-/-}$ LMVECs were incubated for 4 h with DFX or DMOG and migration was studied using the transwell assay. Results are expressed as the mean \pm standard deviation (n \geq 3) of the % number of cells compared to the corresponding untreated cells (set by default as 100%).

Cancers 2025, 17, 1516 12 of 17

We also studied the effect of chemical hypoxia on the expression of PTPRZ1 in HU-VECs and C6 cells. As shown in Supplementary Figure S9, hypoxia or HIF-1 α or HIF-2 α overexpression increased the protein levels of PTPRZ1 in both types of cells.

4. Discussion

In this work, we investigated how hypoxia regulates the PTN expression in endothelial cells and the role of PTN in hypoxia-induced endothelial cell activation. Our data show that hypoxia, including chemical hypoxia, enhances the PTN expression in endothelial cells in line with a previous observation that the PTN expression is elevated in endothelial cells and macrophages in response to acute ischemic brain injuries [17]. PTN shares a 98% homology with midkine, which is up-regulated by hypoxia in pulmonary epithelial cells in a HIF-1 α -dependent manner through transcriptional regulation via the proximal HRE in the midkine promoter [30]. The ptn gene promoter does not seem to have HREs, based on software programs that search for transcription factor binding sites, such as TFBIND (http://tfbind.hgc.jp/, accessed on 13 December 2024) [31] and the Transcription Factor Target Gene Database [32]; however, we cannot exclude that HREs exist in the 3 region of the ptn gene, as is the case, e.g., for the erythropoietin gene [33]. On the other hand, a previous analysis showed that most genes affected by hypoxia lack a HIF-binding site in their promoters [2]. In our study, although the siRNA data suggest that the up-regulation of PTN by hypoxia may be HIF-1 α - and HIF-2 α -independent, the ODNs for HIFs inhibit the PTN up-regulation by low oxygen levels. One explanation may be that the specific inhibition of the individual HIFs does not inhibit the PTN expression because the other HIF isoform may still be sufficient to activate it. This is supported by our data showing that the overexpression of HIF-1 α or HIF-2 α in U87MG cells up-regulates the PTN expression. The hypoxia-induced PTN expression in endothelial cells is also AP-1-dependent, in line with previous studies that have shown the interaction of HIFs with members of the AP-1 family of transcription factors to regulate gene transcription under hypoxic conditions [4,34]. Both HIFs and AP-1 are activated by deferoxamine [35], while DMOG stabilizes and thus up-regulates HIFs [1], but it is not known whether it also activates AP-1. The ptn gene promoter contains two AP-1 HREs that are required for the up-regulation of PTN by hydrogen peroxide, nitric oxide, and fibroblast growth factor 2 [7,36,37] and, based on the data of the present study, for the up-regulation of ptn gene transcription by hypoxia in endothelial and cancer cells that express $\alpha_{\nu}\beta_{3}$ integrin.

The enhanced chemical hypoxia-induced proliferation and migration observed in $Ptn^{-/-}$ compared with $Ptn^{+/+}$ LMVECs agrees with the notion that PTN may act as an endogenous brake for the stimulatory effect of hypoxia in endothelial cells, a hypothesis verified in prostate cancer LNCaP cells with a down-regulated PTN expression. Interestingly, hypoxia inhibits the PTN expression in cells that do not express $\alpha_{\nu}\beta_{3}$ integrin. This aligns with numerous studies showing that the gene regulation by hypoxia is cell context-dependent [38] and with our previous observation that the regulation of the PTN expression by VEGFA differs between cells based on the expression of $\alpha_{\nu}\beta_{3}$ integrin [28]. Although it is unclear how the presence of $\alpha_{\nu}\beta_{3}$ integrin affects how hypoxia impacts PTN expression, the resulting decreased or increased PTN levels align with the stimulatory effect of short-term hypoxia on cell migration. We have previously shown that in cells that do not express $\alpha_{\nu}\beta_{3}$ integrin, such as C6 cells, exogenous PTN inhibits cell migration and down-regulation of the endogenous PTN expression significantly enhances it [9,39]. In contrast, in cells that express $\alpha_{\nu}\beta_{3}$ integrin, exogenous or endogenous PTN stimulates cell migration [9,21,22].

Although hypoxia differentially affects the PTN expression in different types of cells, it enhances the PTPRZ1 protein levels in all cells studied, in line with previous studies

Cancers 2025, 17, 1516 13 of 17

showing that the Ptprz1 gene contains HREs and its expression is directly up-regulated by both HIF-1 α [20] and HIF-2 α [18,19]. To investigate the hypothesis that PTPRZ1 may have a functional role in the effects of hypoxia on endothelial cells, we used endothelial cells derived from Ptprz1^{-/-} mice or LNCaP or C6 cells following the downregulation of PTPRZ1. The impact of hypoxia on endothelial cell proliferation seems to be independent of the expression of PTPRZ1, aligning with the notion that PTPRZ1 mostly affects cell migration [40]. However, the effect of hypoxia was significantly smaller in the migration of Ptprz1^{-/-} LMVECs or in LNCaP and C6 cells, in which the PTPRZ1 expression was downregulated. This might be explained by the observation that when the expression of PTPRZ1 is decreased, HIF- 1α protein levels are increased under normoxic conditions [41] and cell migration is enhanced (this study and [12]). Therefore, the smaller impact of hypoxia on the migration of cells with a decreased PTPRZ1 expression may be attributed to the (already) enhanced basal HIF-1 α levels and migration of these cells under normoxic conditions. Altogether, these data suggest that since PTPRZ1 negatively impacts cell migration, the enhancement of the PTPRZ1 expression by hypoxia may act as a negative regulator of HIF activation, restricting the HIF-dependent effects of hypoxia on cell migration.

Our data show that the impact of PTN and PTPRZ1 in the hypoxia-induced cell migration are differential and do not follow the mirror effect expected for a ligand and its receptor. This is not a surprise and complies with the suggestion that PTPRZ1 is a tyrosine phosphatase receptor that, at least in some cases, is inactivated upon PTN binding [11,12]. Therefore, the loss of PTPRZ1 would mimic the effect of PTN, which is evidenced by the observations that Ptprz1^{-/-} LMVECs have enhanced migration compared with Ptprz1^{+/+} LMVECs and do not respond further to PTN or VEGFA stimulation [12]. On the other hand, the unstimulated $Ptn^{-/-}$ LMVECs have a slightly decreased proliferation and migration compared to their corresponding wild-type cells and have an enhanced response to VEGFA [21], which is in line with our previous observations that although PTN has a modest stimulatory effect on endothelial cell migration by itself, it restricts the stimulatory effect of VEGFA on VEGFR2 activation [10] and endothelial cell proliferation [42] and migration [14,28,42]. This may also explain why in $Ptn^{-/-}$ LMVECs, hypoxia has an enhanced stimulatory effect compared to the corresponding PTN-expressing LMVECs. It is known that PTN acts through numerous receptors besides PTPRZ1 [11], and PTPRZ1 acts as a receptor that regulates the effects of other cytokines, growth factors, and cell adhesion molecules [13], further supporting that we should not expect a mirror effect.

5. Conclusions

Our data suggest that hypoxia regulates the PTN expression in a cell ($\alpha_{\nu}\beta_{3}$ integrin)-dependent manner and up-regulates the PTPRZ1 expression in a HIF-dependent manner. However, through different mechanisms, both PTN and PTPRZ1 seem to restrict the stimulatory effect of hypoxia on cell migration, favoring the notion that they act as endogenous brakes for excessive cell migration (Figure 7).

Cancers 2025, 17, 1516 14 of 17




Figure 7. A schematic representation of the effect of hypoxia on the PTN and PTPRZ1 expression in endothelial cells. Hypoxia activates HIFs and AP-1 to up-regulate the PTN expression in $\alpha_{\rm v}\beta_3$ integrin-expressing cells to restrict the stimulatory effect of hypoxia on cell proliferation and migration. In cells that do not express $\alpha_{\rm v}\beta_3$ integrin, hypoxia downregulates the PTN expression in a HIF- and AP-1-independent manner. In all cases, hypoxia upregulates the expression of PTPRZ1, which is known to negatively regulate (T) HIF1 α [41] and restricts hypoxia-induced cell migration.

Supplementary Materials: The following supporting information can be downloaded at https://www.mdpi.com/article/10.3390/cancers17091516/s1: Table S1. Sequences of the single-stranded ODNs used in the present study; Figure S1A. Effect of different concentrations of DMOG and DFX (200 μM) on PTN protein levels in HUVECs; Figure S1B. Effect of DFX (200 μM) on PTN protein levels in U87MG cells; Figure S2A. Efficiency of cell transfection with siRNAs for HIF-1α or HIF-2α. HIF-1α or HIF-2α mRNA levels 18 h after transfection with the corresponding siRNAs (siHIF-1α or siHIF-2α); Figure S2B. Overexpression of HIF-1α and HIF-2α in U87MG cells; Figure S3. Effect of endogenous PTN expression on chemical hypoxia-induced proliferation and migration of LMVECs; Figure S4. Effect of endogenous PTN expression in hypoxia-induced migration of prostate cancer LNCaP cells; Figure S5. Expression of the $\alpha_V \beta_3$ integrin in the cells used in the present study; Figure S6. Overexpression of HIF-1α and HIF-2α in C6 cells; Figure S7. Effect of endogenous PTPRZ1 expression in chemical hypoxia-induced proliferation and migration of LMVECs; Figure S8. Effect of PTPRZ1 expression on the hypoxia-induced cell migration; Figure S9. Hypoxia enhances the expression of PTPRZ1 in all types of cells.

Author Contributions: Conceptualization, E.P. (Evangelia Poimenidi), P.K. and E.P. (Evangelia Papadimitriou); methodology, E.P. (Evangelia Poimenidi), K.K., E.D., D.K., P.K. and E.P. (Evangelia Papadimitriou); validation, E.P. (Evangelia Poimenidi), P.K. and E.P. (Evangelia Papadimitriou); formal analysis, E.P. (Evangelia Poimenidi), P.K. and E.P. (Evangelia Papadimitriou); investigation, E.P. (Evangelia Poimenidi), K.K., E.D., D.K., P.K. and E.P. (Evangelia Papadimitriou); resources, E.P. (Evangelia Poimenidi), P.K. and E.P. (Evangelia Papadimitriou); writing—original draft preparation, E.P. (Evangelia Poimenidi), P.K. and E.P. (Evangelia Papadimitriou); writing—review and editing, E.P. (Evangelia Poimenidi), K.K., E.D., D.K., P.K. and E.P. (Evangelia Papadimitriou); visualization and supervision, P.K. and E.P. (Evangelia Papadimitriou); project administration, E.P. (Evangelia Papadimitriou); funding acquisition, P.K. and E.P. (Evangelia Papadimitriou). All authors have read and agreed to the published version of the manuscript.

Funding: This work has been financed by FP7 People: Marie Curie Intra European Fellowship (626057) and Matching Funds (to E. Pa.). Greece and the European Union (European Social Fund—ESF) cofinanced part of this research through the Operational Programme «Human Resources Development, Education and Lifelong Learning» in the context of the project "Strengthening Human Resources Research Potential via Doctorate Research" (MIS-5000432), implemented by the State Scholarships Foundation (IKY, scholarship to E.M.).

Cancers 2025, 17, 1516 15 of 17

Institutional Review Board Statement: All procedures performed in studies involving HUVECs and LMVECs were per the ethical standards of the institutional research committee (Bioethics Committee of the University of Patras) and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The mice were bred at the Center for Animal Models of Disease at the University of Patras, Greece (EL13B1004), in a controlled environment of 12 h light/dark cycles and food/water consumption ad libitum. The isolation of LMVECs was designed and approved a priori by the Veterinary Administration of the Prefecture of Western Greece (approval protocol number 388223/1166/8-1-2020), according to Directive 2010/63/EU (http://eurlex.europa.eu/legal-content/EN/TXT/?uri=CELEX:32010L0063, accessed on 8 January 2020).

Informed Consent Statement: Informed consent was not required as HUVECs were obtained from anonymized, discarded tissue (University of Patras IRB No: 13725).

Data Availability Statement: All data supporting this study's findings are available from the corresponding author upon request.

Acknowledgments: The authors are grateful to George Simos, Panagiotis Liakos, and Ilias Mylonis from the Laboratory of Biochemistry, Faculty of Medicine, University of Thessaly, Greece, for kindly providing us with the HIFs plasmids; Heather Himburg and John Chute at the Division of Hematology/Oncology, Broad Stem Cell Research Center, UCLA, Los Angeles, USA, for kindly providing the mice used for endothelial cell isolation in the present study; and Maria Hatziapostolou and Christos Polytarchou at the Department of Biosciences, John van Geest Cancer Research Centre, School of Science and Technology, Nottingham Trent University, Nottingham, UK, for their contribution to transferring them to our facilities.

Conflicts of Interest: The authors declare no conflicts of interest.

Abbreviations

The following abbreviations are used in this manuscript:

HIF hypoxia-inducible transcription factor

PTN pleiotrophin

PTPRZ1 protein tyrosine phosphatase receptor zeta 1 VEGFA₁₆₅ vascular endothelial growth factor A 165

References

- 1. Bruick, R.K.; McKnight, S.L. A conserved family of prolyl-4-hydroxylases that modify HIF. Science 2001, 294, 1337–1340. [CrossRef]
- 2. Benita, Y.; Kikuchi, H.; Smith, A.D.; Zhang, M.Q.; Chung, D.C.; Xavier, R.J. An integrative genomics approach identifies Hypoxia Inducible Factor-1 (HIF-1)-target genes that form the core response to hypoxia. *Nucleic Acids Res.* **2009**, *37*, 4587–4602. [CrossRef] [PubMed]
- 3. Fantozzi, I.; Zhang, S.; Platoshyn, O.; Remillard, C.V.; Cowling, R.T.; Yuan, J.X. Hypoxia increases AP-1 binding activity by enhancing capacitative Ca²⁺ entry in human pulmonary artery endothelial cells. *Am. J. Physiol. Lung Cell. Mol. Physiol.* **2003**, 285, L1233–L1245. [CrossRef] [PubMed]
- 4. Laderoute, K.R. The interaction between HIF-1 and AP-1 transcription factors in response to low oxygen. *Semin. Cell Dev. Biol.* **2005**, *16*, 502–513. [CrossRef] [PubMed]
- 5. Lin, L.; Li, G.; Zhang, W.; Wang, Y.L.; Yang, H. Low-dose aspirin reduces hypoxia-induced sFlt1 release via the JNK/AP-1 pathway in human trophoblast and endothelial cells. *J. Cell. Physiol.* **2019**, 234, 18928–18941. [CrossRef] [PubMed]
- 6. Yadav, S.; Kalra, N.; Ganju, L.; Singh, M. Activator protein-1 (AP-1): A bridge between life and death in lung epithelial (A549) cells under hypoxia. *Mol. Cell. Biochem.* **2017**, *436*, 99–110. [CrossRef]
- 7. Polytarchou, C.; Hatziapostolou, M.; Papadimitriou, E. Hydrogen peroxide stimulates proliferation and migration of human prostate cancer cells through activation of activator protein-1 and up-regulation of the heparin affin regulatory peptide gene. *J. Biol. Chem.* 2005, 280, 40428–40435. [CrossRef]
- 8. Polykratis, A.; Katsoris, P.; Courty, J.; Papadimitriou, E. Characterization of heparin affin regulatory peptide signaling in human endothelial cells. *J. Biol. Chem.* **2005**, *280*, 22454–22461. [CrossRef]

Cancers 2025, 17, 1516 16 of 17

9. Mikelis, C.; Sfaelou, E.; Koutsioumpa, M.; Kieffer, N.; Papadimitriou, E. Integrin $\alpha_v \beta_3$ is a pleiotrophin receptor required for pleiotrophin-induced endothelial cell migration through receptor protein tyrosine phosphatase β/ζ . FASEB J. **2009**, 23, 1459–1469. [CrossRef]

- 10. Lamprou, M.; Kastana, P.; Kofina, F.; Tzoupis, H.; Barmpoutsi, S.; Sajib, M.S.; Koutsioumpa, M.; Poimenidi, E.; Zompra, A.A.; Tassopoulos, D.; et al. Pleiotrophin selectively binds to vascular endothelial growth factor receptor 2 and inhibits or stimulates cell migration depending on $\alpha_V \beta_3$ integrin expression. *Angiogenesis* **2020**, *23*, 621–636. [CrossRef]
- 11. Papadimitriou, E.; Mourkogianni, E.; Ntenekou, D.; Christopoulou, M.; Koutsioumpa, M.; Lamprou, M. On the role of pleiotrophin and its receptors in development and angiogenesis. *Int. J. Dev. Biol.* **2022**, *66*, 115–124. [CrossRef] [PubMed]
- 12. Kastana, P.; Ntenekou, D.; Mourkogianni, E.; Enake, M.K.; Xanthopoulos, A.; Choleva, E.; Marazioti, A.; Nikou, S.; Akwii, R.G.; Papadaki, E.; et al. Genetic deletion or tyrosine phosphatase inhibition of PTPRZ1 activates c-Met to up-regulate angiogenesis and lung adenocarcinoma growth. *Int. J. Cancer* 2023, 153, 1051–1066. [CrossRef] [PubMed]
- 13. Papadimitriou, E.; Kanellopoulou, V.K. Protein Tyrosine Phosphatase Receptor Zeta 1 as a Potential Target in Cancer Therapy and Diagnosis. *Int. J. Mol. Sci.* **2023**, 24, 8093. [CrossRef] [PubMed]
- 14. Koutsioumpa, M.; Poimenidi, E.; Pantazaka, E.; Theodoropoulou, C.; Skoura, A.; Megalooikonomou, V.; Kieffer, N.; Courty, J.; Mizumoto, S.; Sugahara, K.; et al. Receptor protein tyrosine phosphatase beta/zeta is a functional binding partner for vascular endothelial growth factor. *Mol. Cancer* 2015, 14, 19. [CrossRef]
- Antoine, M.; Tag, C.G.; Wirz, W.; Borkham-Kamphorst, E.; Sawitza, I.; Gressner, A.M.; Kiefer, P. Upregulation of pleiotrophin expression in rat hepatic stellate cells by PDGF and hypoxia: Implications for its role in experimental biliary liver fibrogenesis. *Biochem. Biophys. Res. Commun.* 2005, 337, 1153–1164. [CrossRef]
- 16. Li, J.; Wei, H.; Chesley, A.; Moon, C.; Krawczyk, M.; Volkova, M.; Ziman, B.; Margulies, K.B.; Talan, M.; Crow, M.T.; et al. The pro-angiogenic cytokine pleiotrophin potentiates cardiomyocyte apoptosis through the inhibition of endogenous AKT/PKB activity. *J. Biol. Chem.* **2007**, 282, 34984–34993. [CrossRef] [PubMed]
- 17. Yeh, H.J.; He, Y.Y.; Xu, J.; Hsu, C.Y.; Deuel, T.F. Upregulation of pleiotrophin gene expression in developing microvasculature, macrophages, and astrocytes after acute ischemic brain injury. *J. Neurosci.* **1998**, *18*, 3699–3707. [CrossRef]
- 18. Wang, V.; Davis, D.A.; Haque, M.; Huang, L.E.; Yarchoan, R. Differential gene up-regulation by hypoxia-inducible factor- 1α and hypoxia-inducible factor- 2α in HEK293T cells. *Cancer Res.* **2005**, *65*, 3299–3306. [CrossRef]
- 19. Wang, V.; Davis, D.A.; Veeranna, R.P.; Haque, M.; Yarchoan, R. Characterization of the activation of protein tyrosine phosphatase, receptor-type, Z polypeptide 1 (PTPRZ1) by hypoxia-inducible factor-2 alpha. *PLoS ONE* **2010**, *5*, e9641. [CrossRef]
- 20. Chen, M.; Karimpour, P.A.; Elliott, A.; He, D.; Knifley, T.; Liu, J.; Wang, C.; O'Connor, K.L. Integrin α6β4 Upregulates PTPRZ1 Through UCHL1-Mediated Hif-1α Nuclear Accumulation to Promote Triple-Negative Breast Cancer Cell Invasive Properties. *Cancers* 2024, 16, 3683. [CrossRef]
- 21. Choleva, E.; Menounou, L.; Ntenekou, D.; Kastana, P.; Tzoupis, H.; Katraki-Pavlou, S.; Drakopoulou, M.; Spyropoulos, D.; Andrikopoulou, A.; Kanellopoulou, V.; et al. Targeting the interaction of pleiotrophin and VEGFA₁₆₅ with protein tyrosine phosphatase receptor zeta 1 inhibits endothelial cell activation and angiogenesis. *Eur. J. Pharmacol.* **2024**, *977*, 176692. [CrossRef] [PubMed]
- 22. Hatziapostolou, M.; Delbe, J.; Katsoris, P.; Polytarchou, C.; Courty, J.; Papadimitriou, E. Heparin affin regulatory peptide is a key player in prostate cancer cell growth and angiogenicity. *Prostate* **2005**, *65*, 151–158. [CrossRef] [PubMed]
- 23. Nauta, T.D.; Duyndam, M.C.; Weijers, E.M.; van Hinsbergh, V.M.; Koolwijk, P. HIF-2α Expression Regulates Sprout Formation into 3D Fibrin Matrices in Prolonged Hypoxia in Human Microvascular Endothelial Cells. *PLoS ONE* **2016**, *11*, e0160700; Erratum in *PLoS ONE* **2016**, *11*, e0163840. https://doi.org/10.1371/journal.pone.0163840. [CrossRef]
- 24. Wang, G.L.; Semenza, G.L. Desferrioxamine induces erythropoietin gene expression and hypoxia-inducible factor 1 DNA-binding activity: Implications for models of hypoxia signal transduction. *Blood* **1993**, *82*, 3610–3615. [CrossRef]
- 25. Mylonis, I.; Chachami, G.; Samiotaki, M.; Panayotou, G.; Paraskeva, E.; Kalousi, A.; Georgatsou, E.; Bonanou, S.; Simos, G. Identification of MAPK phosphorylation sites and their role in the localization and activity of hypoxia-inducible factor-1α. *J. Biol. Chem.* **2006**, 281, 33095–33106. [CrossRef]
- 26. Befani, C.; Mylonis, I.; Gkotinakou, I.M.; Georgoulias, P.; Hu, C.J.; Simos, G.; Liakos, P. Cobalt stimulates HIF-1-dependent but inhibits HIF-2-dependent gene expression in liver cancer cells. *Int. J. Biochem. Cell Biol.* **2013**, 45, 2359–2368. [CrossRef] [PubMed]
- 27. Koutsioumpa, M.; Polytarchou, C.; Courty, J.; Zhang, Y.; Kieffer, N.; Mikelis, C.; Skandalis, S.S.; Hellman, U.; Iliopoulos, D.; Papadimitriou, E. Interplay between $\alpha_v \beta_3$ integrin and nucleolin regulates human endothelial and glioma cell migration. *J. Biol. Chem.* **2013**, 288, 343–354. [CrossRef]
- 28. Poimenidi, E.; Theodoropoulou, C.; Koutsioumpa, M.; Skondra, L.; Droggiti, E.; van den Broek, M.; Koolwijk, P.; Papadimitriou, E. Vascular endothelial growth factor A (VEGF-A) decreases expression and secretion of pleiotrophin in a VEGF receptor-independent manner. *Vasc. Pharmacol.* **2016**, *80*, 11–19. [CrossRef]
- 29. Yang, Y.T.; Ju, T.C.; Yang, D.I. Induction of hypoxia inducible factor-1 attenuates metabolic insults induced by 3-nitropropionic acid in rat C6 glioma cells. *J. Neurochem.* **2005**, *93*, 513–525. [CrossRef]

Cancers 2025, 17, 1516 17 of 17

30. Reynolds, P.R.; Mucenski, M.L.; Le Cras, T.D.; Nichols, W.C.; Whitsett, J.A. Midkine is regulated by hypoxia and causes pulmonary vascular remodeling. *J. Biol. Chem.* **2004**, *279*, 37124–37132. [CrossRef]

- 31. Tsunoda, T.; Takagi, T. Estimating transcription factor bindability on DNA. Bioinformatics 1999, 15, 622–630. [CrossRef] [PubMed]
- 32. Plaisier, C.L.; O'Brien, S.; Bernard, B.; Reynolds, S.; Simon, Z.; Toledo, C.M.; Ding, Y.; Reiss, D.J.; Paddison, P.J.; Baliga, N.S. Causal Mechanistic Regulatory Network for Glioblastoma Deciphered Using Systems Genetics Network Analysis. *Cell Syst.* **2016**, 3, 172–186. [CrossRef]
- 33. Orlando, I.M.C.; Lafleur, V.N.; Storti, F.; Spielmann, P.; Crowther, L.; Santambrogio, S.; Schödel, J.; Hoogewijs, D.; Mole, D.R.; Wenger, R.H. Distal and proximal hypoxia response elements cooperate to regulate organ-specific erythropoietin gene expression. *Haematologica* **2020**, 105, 2774–2784. [CrossRef]
- 34. Michiels, C.; Minet, E.; Michel, G.; Mottet, D.; Piret, J.P.; Raes, M. HIF-1 and AP-1 cooperate to increase gene expression in hypoxia: Role of MAP kinases. *IUBMB Life* **2001**, *52*, 49–53. [CrossRef] [PubMed]
- 35. Huang, X.; Dai, J.; Huang, C.; Zhang, Q.; Bhanot, O.; Pelle, E. Deferoxamine synergistically enhances iron-mediated AP-1 activation: A showcase of the interplay between extracellular-signal-regulated kinase and tyrosine phosphatase. *Free Radic. Res.* **2007**, *41*, 1135–1142. [CrossRef] [PubMed]
- Hatziapostolou, M.; Polytarchou, C.; Katsoris, P.; Courty, J.; Papadimitriou, E. Heparin affin regulatory peptide/pleiotrophin mediates fibroblast growth factor 2 stimulatory effects on human prostate cancer cells. J. Biol. Chem. 2006, 281, 32217–32226.
 [CrossRef] [PubMed]
- 37. Polytarchou, C.; Hatziapostolou, M.; Poimenidi, E.; Mikelis, C.; Papadopoulou, A.; Parthymou, A.; Papadimitriou, E. Nitric oxide stimulates migration of human endothelial and prostate cancer cells through up-regulation of pleiotrophin expression and its receptor protein tyrosine phosphatase β/ζ. *Int. J. Cancer* **2009**, *124*, 1785–1793. [CrossRef] [PubMed]
- 38. Chi, J.T.; Wang, Z.; Nuyten, D.S.; Rodriguez, E.H.; Schaner, M.E.; Salim, A.; Wang, Y.; Kristensen, G.B.; Helland, A.; Børresen-Dale, A.L.; et al. Gene expression programs in response to hypoxia: Cell type specificity and prognostic significance in human cancers. *PLoS Med.* 2006, 3, e47. [CrossRef] [PubMed]
- 39. Parthymou, A.; Lampropoulou, E.; Mikelis, C.; Drosou, G.; Papadimitriou, E. Heparin affin regulatory peptide/pleiotrophin negatively affects diverse biological activities in C6 glioma cells. *Eur. J. Cell Biol.* **2008**, *87*, 17–29. [CrossRef]
- 40. Lu, K.V.; Jong, K.A.; Kim, G.Y.; Singh, J.; Dia, E.Q.; Yoshimoto, K.; Wang, M.Y.; Cloughesy, T.F.; Nelson, S.F.; Mischel, P.S. Differential induction of glioblastoma migration and growth by two forms of pleiotrophin. *J. Biol. Chem.* **2005**, 280, 26953–26964. [CrossRef]
- Mourkogianni, E.; Karavasili, K.; Xanthopoulos, A.; Enake, M.K.; Menounou, L.; Papadimitriou, E. Pleiotrophin Activates cMet- and mTORC1-Dependent Protein Synthesis through PTPRZ1-The Role of α_Vβ₃ Integrin. *Int. J. Mol. Sci.* 2024, 25, 10839. [CrossRef] [PubMed]
- 42. Héroult, M.; Bernard-Pierrot, I.; Delbé, J.; Hamma-Kourbali, Y.; Katsoris, P.; Barritault, D.; Papadimitriou, E.; Plouet, J.; Courty, J. Heparin affin regulatory peptide binds to vascular endothelial growth factor (VEGF) and inhibits VEGF-induced angiogenesis. Oncogene 2004, 23, 1745–1753. [CrossRef] [PubMed]

Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.